FDA Updating Antibiotic Guidances, But Is It Too Late For Some Sponsors?
Executive Summary
It was supposed to be a year with a wealth of novel antibiotics, but regulatory concerns turned 2008 from a year of banner antibiotic approvals into a sizeable crop of action letters. Now the delays are taking a serious toll, causing some sponsors to drastically restructure in the face of uncertain and evolving regulatory standards
You may also be interested in...
Antibiotics Could Get Double Exclusivity Under House Bill; FDA Makes Its Own Moves
Five years of additional exclusivity, priority review and fast-track status are the carrots offered in legislation introduced by Rep. Phil Gingrey, R.-Ga., June 15 to entice drug makers to develop antimicrobials for drug-resistant pathogens.
Antibiotics Could Get Double Exclusivity Under House Bill; FDA Makes Its Own Moves
Five years of additional exclusivity, priority review and fast-track status are the carrots offered in legislation introduced by Rep. Phil Gingrey, R.-Ga., June 15 to entice drug makers to develop antimicrobials for drug-resistant pathogens.
Novartis Licenses Worldwide Rights To Paratek's Broad-Spectrum Antibiotic
Clarified regulatory path for antibiotics may have helped produce potentially lucrative deal for the private biotech.